MA42439A - Agents, utilisations et procédés pour le traitement d'une synucléinopathie - Google Patents

Agents, utilisations et procédés pour le traitement d'une synucléinopathie

Info

Publication number
MA42439A
MA42439A MA042439A MA42439A MA42439A MA 42439 A MA42439 A MA 42439A MA 042439 A MA042439 A MA 042439A MA 42439 A MA42439 A MA 42439A MA 42439 A MA42439 A MA 42439A
Authority
MA
Morocco
Prior art keywords
synucleinopathy
agents
treatment
methods
Prior art date
Application number
MA042439A
Other languages
English (en)
Other versions
MA42439B1 (fr
Inventor
Ann-Louise Bergström
Karina Fog
Pekka Kallunki
Ibrahim John Malik
Liliana Christina Pereira Montezinho
Paul Parren
Rik Rademaker
David Satijn
Florence Sotty
Den Brink Edward Van
Louise Buur Vesterager
Tom Vink
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA42439A publication Critical patent/MA42439A/fr
Publication of MA42439B1 publication Critical patent/MA42439B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
MA42439A 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie MA42439B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
PCT/EP2016/066476 WO2017009312A1 (fr) 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP16738736.4A EP3322722B1 (fr) 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie

Publications (2)

Publication Number Publication Date
MA42439A true MA42439A (fr) 2018-05-23
MA42439B1 MA42439B1 (fr) 2025-05-30

Family

ID=54013851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42439A MA42439B1 (fr) 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie

Country Status (40)

Country Link
US (12) US10800836B2 (fr)
EP (2) EP4582144A3 (fr)
JP (4) JP7012004B2 (fr)
KR (2) KR20250051158A (fr)
CN (4) CN107709361A (fr)
AR (1) AR105336A1 (fr)
AU (1) AU2016292896B2 (fr)
CL (1) CL2018000075A1 (fr)
CO (1) CO2017012941A2 (fr)
CR (2) CR20180021A (fr)
DK (1) DK3322722T3 (fr)
DO (1) DOP2018000013A (fr)
EA (1) EA036499B1 (fr)
EC (1) ECSP18002645A (fr)
ES (1) ES3028882T3 (fr)
FI (1) FI3322722T3 (fr)
GB (1) GB201512203D0 (fr)
GE (2) GEAP202014670A (fr)
HR (1) HRP20250624T1 (fr)
HU (1) HUE071541T2 (fr)
IL (1) IL256501B (fr)
JO (1) JO3692B1 (fr)
LT (1) LT3322722T (fr)
MA (1) MA42439B1 (fr)
MX (2) MX2018000504A (fr)
MY (1) MY194944A (fr)
NI (1) NI201800006A (fr)
PE (1) PE20181049A1 (fr)
PH (1) PH12018500016A1 (fr)
PL (1) PL3322722T3 (fr)
PT (1) PT3322722T (fr)
RS (1) RS66840B1 (fr)
RU (1) RU2765303C2 (fr)
SI (1) SI3322722T1 (fr)
SV (1) SV2018005612A (fr)
TN (1) TN2018000005A1 (fr)
TW (1) TWI729992B (fr)
UA (1) UA125501C2 (fr)
WO (1) WO2017009312A1 (fr)
ZA (1) ZA201708607B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
EP3555127B1 (fr) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, utilisations et procédés
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucleine et leurs utilisations
IL269550B2 (en) 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
EP3618870A4 (fr) * 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania Anticorps monoclonaux contre les fibrilles d'alpha-synucléine
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
KR102508933B1 (ko) * 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (fr) 2017-12-14 2022-03-30 ABL Bio Inc. Anticorps bispécifique contre a-syn/igf1r et utilisation associée
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2019147904A1 (fr) * 2018-01-26 2019-08-01 Quantum-Si Incorporated Appel de bases et d'impulsions activé par apprentissage automatique pour dispositifs de séquençage
US20210032369A1 (en) * 2018-02-12 2021-02-04 The Scripps Research Institute Methods related to parkinson?s disease and synucleinopathies
CA3108986A1 (fr) * 2018-08-09 2020-02-13 Ventana Medical Systems, Inc. Determination de la maladie de parkinson
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
JP7689373B2 (ja) * 2019-04-18 2025-06-06 エイシー イミューン ソシエテ アノニム 治療及び診断のための新規分子
JP2022531177A (ja) * 2019-04-29 2022-07-06 トーマス・ジェファーソン・ユニバーシティ 神経変性障害を治療するための方法
CA3159964A1 (fr) * 2019-12-04 2021-06-10 Ac Immune Sa Nouvelles molecules de therapie et de diagnostic
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
JP2024534901A (ja) * 2021-09-01 2024-09-26 ヴァクシニティ， インコーポレイテッド シヌクレイノパチーの予防及び治療のための方法
EP4401770A2 (fr) 2021-09-16 2024-07-24 H. Lundbeck A/S Compositions et méthodes de traitement des synucléinopathies
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
WO2024177999A2 (fr) * 2023-02-21 2024-08-29 The Regents Of The University Of Michigan Molécules de liaison à l'alpha-synucléine agrégées humaines
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途
WO2025076635A1 (fr) * 2023-10-12 2025-04-17 Universite Laval ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS
WO2025186235A1 (fr) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions et méthodes de traitement de l'atrophie multisystématisée (ams)

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988004777A1 (fr) 1986-12-15 1988-06-30 Ultra Diagnostics Corporation Reactifs de phtalocyanine monomeres
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
WO1992022645A1 (fr) 1991-06-14 1992-12-23 Genpharm International, Inc. Animaux transgeniques non humains presentant une deficience immunitaire
CA2113113A1 (fr) 1991-07-08 1993-01-21 Simon W. Kantor Copolymere sequence a cristaux liquides thermotropiques
WO1994019935A1 (fr) 1993-03-09 1994-09-15 Genzyme Corporation Isolement de constituants d'interet du lait
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (fr) 1999-08-24 2007-02-21 Medarex, Inc. Anticorps contre l'antigene ctla-4 humain et utilisation
WO2002004482A1 (fr) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Procedes pour la prevention des degats relatifs aux tissus nerveux et pour le traitement des maladies liees a l'alpha-synucleine
CA2430013C (fr) 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
WO2003000714A2 (fr) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions et procedes pour la prevention d'agregation de proteines dans des maladies neurodegeneratives
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
PL2361928T3 (pl) 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (fr) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Anticorps a l'alpha-synucleine
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
EA013752B1 (ru) * 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
WO2007011907A2 (fr) * 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
CA2631184A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP2154969B1 (fr) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Traitement des synucléinopathies
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
BRPI1015472A2 (pt) 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
EP2366714A1 (fr) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Auto-anticorps d'origine naturelle contre l'alpha-synucléine qui inhibent l'agrégation et la cytotoxicité de l'alpha-synucléine
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
CA2813493C (fr) 2010-10-11 2019-07-09 University Of Zurich Anticorps anti-tau humain
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
RS63930B1 (sr) * 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP3563849A3 (fr) 2012-10-25 2020-02-12 The General Hospital Corporation Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP2018515607A (ja) 2015-05-07 2018-06-14 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 神経変性疾患を処置する組成物および方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10160800B2 (en) 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Also Published As

Publication number Publication date
CN107709361A (zh) 2018-02-16
MY194944A (en) 2022-12-27
HRP20250624T1 (hr) 2025-07-18
AU2016292896B2 (en) 2022-02-24
US10647764B2 (en) 2020-05-12
US20210061892A1 (en) 2021-03-04
KR102793383B1 (ko) 2025-04-08
WO2017009312A1 (fr) 2017-01-19
CN121824750A (zh) 2026-04-10
EP3322722A1 (fr) 2018-05-23
GEAP202014670A (en) 2020-05-11
CA2989735A1 (fr) 2017-01-19
ECSP18002645A (es) 2018-03-31
CN121736097A (zh) 2026-03-27
CO2017012941A2 (es) 2018-03-09
MX2018000504A (es) 2018-04-30
US20180127492A1 (en) 2018-05-10
US10800836B2 (en) 2020-10-13
US11542323B2 (en) 2023-01-03
JP7138322B2 (ja) 2022-09-16
US20210147522A1 (en) 2021-05-20
IL256501B (en) 2021-10-31
US11524995B2 (en) 2022-12-13
KR20180029205A (ko) 2018-03-20
EP4582144A3 (fr) 2025-07-16
HUE071541T2 (hu) 2025-09-28
US20190367595A1 (en) 2019-12-05
US20210054057A1 (en) 2021-02-25
CL2018000075A1 (es) 2018-05-11
CR20230300A (es) 2023-08-25
PT3322722T (pt) 2025-05-21
MA42439B1 (fr) 2025-05-30
RS66840B1 (sr) 2025-06-30
JP7608404B2 (ja) 2025-01-06
BR112017027506A2 (pt) 2018-09-11
US20180179271A1 (en) 2018-06-28
SV2018005612A (es) 2018-07-20
UA125501C2 (uk) 2022-04-13
US10358483B2 (en) 2019-07-23
NI201800006A (es) 2018-10-18
RU2017145653A3 (fr) 2019-11-21
EA201792616A1 (ru) 2018-06-29
CN115925921A (zh) 2023-04-07
PH12018500016A1 (en) 2018-07-09
US20180127491A1 (en) 2018-05-10
GEP20207151B (en) 2020-09-25
JP2022174131A (ja) 2022-11-22
US20180179270A1 (en) 2018-06-28
DOP2018000013A (es) 2018-04-15
RU2765303C2 (ru) 2022-01-28
JP2025041734A (ja) 2025-03-26
GB201512203D0 (en) 2015-08-19
JP2018529634A (ja) 2018-10-11
US10647763B2 (en) 2020-05-12
JP7012004B2 (ja) 2022-02-10
US20190367594A1 (en) 2019-12-05
US11421024B2 (en) 2022-08-23
US20170015739A1 (en) 2017-01-19
NZ738315A (en) 2024-12-20
PL3322722T3 (pl) 2025-06-30
ZA201708607B (en) 2019-05-29
TN2018000005A1 (en) 2019-07-08
JP2021191763A (ja) 2021-12-16
DK3322722T3 (da) 2025-05-26
HK1254358A1 (en) 2019-07-19
TW201716440A (zh) 2017-05-16
CR20180021A (es) 2018-03-13
US10358484B2 (en) 2019-07-23
US10358482B2 (en) 2019-07-23
US20190382473A1 (en) 2019-12-19
MX2023009483A (es) 2023-08-22
TWI729992B (zh) 2021-06-11
FI3322722T3 (fi) 2025-06-05
KR20250051158A (ko) 2025-04-16
IL256501A (en) 2018-02-28
EP3322722B1 (fr) 2025-03-05
SI3322722T1 (sl) 2025-06-30
JO3692B1 (ar) 2020-08-27
LT3322722T (lt) 2025-06-10
AU2016292896A1 (en) 2018-01-18
EA036499B1 (ru) 2020-11-17
RU2017145653A (ru) 2019-08-13
US10364285B2 (en) 2019-07-30
AR105336A1 (es) 2017-09-27
ES3028882T3 (en) 2025-06-20
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
US20230312693A1 (en) 2023-10-05
EP4582144A2 (fr) 2025-07-09

Similar Documents

Publication Publication Date Title
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3307713A4 (fr) Inhibiteurs d'ezh2 pour traiter le lymphome
EP3302501A4 (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
EP3390357A4 (fr) Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3267995A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose
EP3359157A4 (fr) Procédés et compositions pour le traitement de tumeurs et de cancers métastasés et résistants
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3353144A4 (fr) Composés efficaces pour traiter l'hépatotoxicité et des stéatoses hépatiques, et utilisations de ceux-ci
EP3621600A4 (fr) Procédés pour le traitement d'un glioblastome récurrent (rgbm)
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3294305A4 (fr) Seringues et procédés d'utilisation de celles-ci pour traiter une vessie hyperactive
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
MA49633A (fr) Agents, utilisations et procédés de traitement